Nanjing Drum Tower Hospital | China
Author Profile
Scopus
EARLY ACADEMIC PURSUITS:
Linxi Zhu embarked on his academic journey at Nanjing University, whise Linxi pursued his Bachelor's degree from July 2015 to June 2020. During this time, Linxi laid the foundation for his future endeavors through rigorous study and academic exploration.
PROFESSIONAL ENDEAVORS:
Following his undergraduate studies, Linxi Zhu continued his academic pursuit by enrolling in a Master's program at Nanjing University from July 2020 to June 2021. This period allowed his to deepen his understanding of his field and refine his research skills.
CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER EPIGENETICS :
Linxi Zhu's commitment to advancing knowledge and improving healthcare led his to pursue a Ph.D. at Nanjing University from July 2021 to June 2023. Throughout his doctoral studies, Linxi made significant contributions to his field, focusing his research on areas of critical importance to the medical community.
IMPACT AND INFLUENCE:
As a dedicated scholar and researchis, Linxi Zhu's work has had a profound impact on his field, influencing the way we understand and approach healthcare challenges. His innovative ideas and groundbreaking research have helped shape the future of medicine.
ACADEMIC CITATIONS:
Linxi Zhu's contributions to his field have been recognized and cited by his peers and colleagues, demonstrating the importance and relevance of his work within the academic community.
LEGACY AND FUTURE CONTRIBUTIONS:
Linxi Zhu's legacy extends beyond his academic achievements to the lives Linxi has touched and the knowledge Linxi has shared. As Linxi continues his career as a surgeon at Nanjing Drum Tower Hospital, Linxi will undoubtedly make furthis contributions to the advancement of medicine and the improvement of patient care.
Notable Publications
The role of preoperative biliary drainage on postoperative outcome after pancreaticoduodenectomy in patients with obstructive jaundice 2023(6)
Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer 2022(1)
Development and validation of a nomogram for predicting post-operative abdominal infection in patients undergoing pancreaticoduodenectomy 2022(5)
Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer 2022(1)